Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Vascular access in super-aged patients

View through CrossRef
Purpose In developed countries, dialysis patients are aging along with the general population. The choice of vascular access (VA) is a more complex decision among elderly patients and is not specifically addressed by clinical practice guidelines. We investigated the relationship between the VA type at dialysis initiation in elderly patients and their prognosis, as well as the selection of the optimal VA type. Methods We conducted a retrospective observational cohort study of consecutive adult patients (age ≥18 years) as their first form of renal replacement therapy (RRT) between January 1, 2003, and December 31, 2010. For this study, VA included both arteriovenous fistula (AVF) and temporary central venous catheter (CVC). Results A total of 402 patients were included in this study. The percentage of patients who started dialysis with CVC increased with age, and 63% of those were over 80 years. The survival rate in the group of elderly patients (≥70 years) using CVC at dialysis initiation was significantly lower. In contrast, the survival rates were comparable between nonelderly patients (<70 years) using CVC or AVF. One hundred and thirty patients were super-aged (≥80 years). In super-aged patients (≥80 years) and aged patients (70-79 years), dialysis initiation with CVC was correlated with a significantly poorer survival rate than dialysis initiation with AVF. The survival rates were comparable between the low CRP group (<1.8 mg/dL) using CVC or AVF. Conclusions The initiation of dialysis with temporary CVC is not a risk factor of death in nonelderly patients (<70 years). On the other hand, in elderly (≥70 years) and super-aged (≥80 years) patients, dialysis initiation with CVC increased the risk of death, but they had to start dialysis with CVC on an emergency basis because of their clinical condition, that is, inflammations.
Title: Vascular access in super-aged patients
Description:
Purpose In developed countries, dialysis patients are aging along with the general population.
The choice of vascular access (VA) is a more complex decision among elderly patients and is not specifically addressed by clinical practice guidelines.
We investigated the relationship between the VA type at dialysis initiation in elderly patients and their prognosis, as well as the selection of the optimal VA type.
Methods We conducted a retrospective observational cohort study of consecutive adult patients (age ≥18 years) as their first form of renal replacement therapy (RRT) between January 1, 2003, and December 31, 2010.
For this study, VA included both arteriovenous fistula (AVF) and temporary central venous catheter (CVC).
Results A total of 402 patients were included in this study.
The percentage of patients who started dialysis with CVC increased with age, and 63% of those were over 80 years.
The survival rate in the group of elderly patients (≥70 years) using CVC at dialysis initiation was significantly lower.
In contrast, the survival rates were comparable between nonelderly patients (<70 years) using CVC or AVF.
One hundred and thirty patients were super-aged (≥80 years).
In super-aged patients (≥80 years) and aged patients (70-79 years), dialysis initiation with CVC was correlated with a significantly poorer survival rate than dialysis initiation with AVF.
The survival rates were comparable between the low CRP group (<1.
8 mg/dL) using CVC or AVF.
Conclusions The initiation of dialysis with temporary CVC is not a risk factor of death in nonelderly patients (<70 years).
On the other hand, in elderly (≥70 years) and super-aged (≥80 years) patients, dialysis initiation with CVC increased the risk of death, but they had to start dialysis with CVC on an emergency basis because of their clinical condition, that is, inflammations.

Related Results

Magic graphs
Magic graphs
DE LA TESIS<br/>Si un graf G admet un etiquetament super edge magic, aleshores G es diu que és un graf super edge màgic. La tesis està principalment enfocada a l'estudi del c...
Product of digraphs, (super) edge-magic valences and related problems
Product of digraphs, (super) edge-magic valences and related problems
Discrete Mathematics, and in particular Graph Theory, has gained a lot of popularity during the last 7 decades. Among the many branches in Graph Theory, graph labelings has experim...
[RETRACTED] ACV Super Slim Gummies Reviews Scam Or Legit Updated 2022 – Must-See Worth Buying? v1
[RETRACTED] ACV Super Slim Gummies Reviews Scam Or Legit Updated 2022 – Must-See Worth Buying? v1
[RETRACTED]➪ACV Super Slim Gummies - Official Website Link - Click Here To Buy❤️ ✪Product Name ➯ ACV Super Slim Gummies UK✪Main Benefits ➯ Can help you with all your overweight i...
[RETRACTED] ACV Super Slim Gummies Reviews Scam Or Legit Updated 2022 – Must-See Worth Buying? v1
[RETRACTED] ACV Super Slim Gummies Reviews Scam Or Legit Updated 2022 – Must-See Worth Buying? v1
[RETRACTED]➪ACV Super Slim Gummies - Official Website Link - Click Here To Buy❤️ ✪Product Name ➯ ACV Super Slim Gummies UK✪Main Benefits ➯ Can help you with all your overweight i...
Quantitative nanoscale imaging of synaptic protein organization
Quantitative nanoscale imaging of synaptic protein organization
The arrival of super-resolution techniques has driven researchers to explore biological areas that were unreachable before. Such techniques not only allowed the improvement of spat...
Super-lncRNAs: identification of lncRNAs that target super-enhancers via RNA:DNA:DNA triplex formation
Super-lncRNAs: identification of lncRNAs that target super-enhancers via RNA:DNA:DNA triplex formation
Super-enhancers are characterized by high levels of Mediator binding and are major contributors to the expression of their associated genes. They exhibit high levels of local chrom...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top